Teva Pharmaceuticals
TEVA
779 hedge funds and large institutions have $26B invested in Teva Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 77 funds opening new positions, 256 increasing their positions, 300 reducing their positions, and 66 closing their positions.
172% more call options, than puts
Call options by funds: $1.58B | Put options by funds: $579M
17% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 66
2.48% more ownership
Funds ownership: 49.78% → 52.26% (+2.5%)
1% more funds holding
Funds holding: 770 → 779 (+9)
4% more capital invested
Capital invested by funds: $24.9B → $26B (+$1.1B)
15% less repeat investments, than reductions
Existing positions increased: 256 | Existing positions reduced: 300
16% less funds holding in top 10
Funds holding in top 10: 58 → 49 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$651M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$570M |
| 3 |
Lazard Asset Management
New York
|
+$526M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$292M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$256M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$937M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$536M |
| 3 |
SFM
Soros Fund Management
New York
|
-$155M |
| 4 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
-$126M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$112M |
TEVA Hedge Fund Activity: Q2 2014 in Review
779 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2014, worth a combined $26B — up 4.4% from $24.9B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new TEVA positions and 66 closed out — a net gain of 11 holders — while 256 added to existing stakes and 300 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $651M. The largest seller was Wellington Management Group, cutting an estimated $937M.
- 779 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2014, up from 770 in Q1 2014.
- Funds reported $26B of Teva Pharmaceuticals stock for Q2 2014, up 4.4% quarter-over-quarter.
- 77 funds opened new Teva Pharmaceuticals positions in Q2 2014 and 66 closed out, a net change of +11 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2014 was Fidelity Investments, an estimated $651M added.
- The largest Teva Pharmaceuticals seller in Q2 2014 was Wellington Management Group, an estimated $937M sold.
Based on aggregated 13F filings for Q2 2014.